BioCryst Adds $350 Million in New Financing with Royalty Pharma and OMERS Capital Markets
November 22, 2021 07:00 ET
|
BioCryst Pharmaceuticals, Inc.
—Provides funding for BCX9930/oral Factor D program across multiple indications— —Agreements supported by strength of ORLADEYO® (berotralstat) launch and confidence in future opportunity— NEW YORK,...
BioCryst Reports First Quarter 2020 Financial Results and Upcoming Key Milestones
May 06, 2020 07:00 ET
|
BioCryst Pharmaceuticals, Inc.
—Berotralstat approval/launch timelines in U.S., Japan, EU remain on track— —Early clinical data supports BCX9930 as oral monotherapy for complement-mediated diseases— —Patient dosing underway in...
BioCryst Reports Data From Phase 1 Trial of BCX9930 and Announces Plans to Advance Program Into Proof of Concept Study in PNH Patients
October 28, 2019 06:59 ET
|
BioCryst Pharmaceuticals, Inc.
—Phase 1 data showed rapid, sustained and >95% inhibition of alternative pathway of complement system with 100 mg of oral BCX9930 BID— —BCX9930 safe and generally well tolerated— —Part 1 SAD and...
Biocryst Begins Enrollment of Phase 1 Trial of BCX9930, an Oral Factor D Inhibitor for Complement-Mediated Diseases
June 27, 2019 16:15 ET
|
BioCryst Pharmaceuticals, Inc.
—Data expected in Q4 2019— —BCX9930 showed high potency, specificity, suppression of hemolysis and wide safety margin in preclinical studies— RESEARCH TRIANGLE PARK, N.C., June 27, 2019 (GLOBE...
BioCryst Appoints Rare Disease Expert Theresa Heggie to Board of Directors
November 20, 2018 07:00 ET
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., Nov. 20, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed Theresa Heggie to its Board of Directors. ...
BioCryst Reports Third Quarter 2018 Financial Results
November 06, 2018 07:00 ET
|
BioCryst Pharmaceuticals, Inc.
APeX-2 study enrollment completed, results on-track for Q2 2019 RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced...
BioCryst to Present Abstracts at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology
November 05, 2018 07:00 ET
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present three abstracts at the upcoming Annual...